Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients

Fig. 1

Overview of disease burden and ctDNA for 32 patients with melanoma. Patients are ordered according to metabolic tumour burden (MTB). Other indications of tumour burden such as metabolic tumour volume (MTV) and site of metastasis are compared with circulating tumour DNA (ctDNA, copies/mL of plasma) levels and site of metastasis. CtDNA was measured by droplet digital PCR targeting the mutations indicated. *denotes cases for which cfDNA was extracted from 1 mL of plasma. †denotes KIT L576P, ‡denotes NRAS Q61L

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us